Target intelligence / Profile preview

Terminal D-alanyl-D-alanine of peptidoglycan precursor

Molecular classification
Other, Cell wall precursor (peptidoglycan precursor terminal motif)
01

Overview

The **terminal D-alanyl-D-alanine** of peptidoglycan precursor is a specific dipeptide motif located at the end of the pentapeptide stem of the nascent peptidoglycan subunits in most bacteria[3][6][7][2]. These peptidoglycan precursors are critical intermediates in bacterial cell wall biosynthesis: they are transported to the outer face of the cytoplasmic membrane, where they are polymerized and cross-linked to form the rigid peptidoglycan mesh that protects bacterial cells from osmotic pressure and environmental stress[1][6][2]. The D-alanyl-D-alanine motif is the recognition site for both cell wall-assembling enzymes (penicillin-binding proteins, transpeptidases) and for glycopeptide antibiotics such as vancomycin, which bind tightly to it and thereby prevent proper formation and cross-linking of the peptidoglycan, leading to bacterial death[6][2]. Resistance to vancomycin is associated with mutations in bacteria that replace this motif, most commonly with D-alanyl-D-lactate, thus reducing antibiotic affinity[6]. This motif is not a protein or receptor, but a chemically well-defined bacterium-specific peptide structure, and is a validated therapeutic target for several clinically-important antibiotics.

Other names
D-Ala-D-Ala motifTerminal D-alanyl-D-alaninePeptidoglycan D-Ala-D-AlaD-alanyl-D-alanine terminus
02

Mechanism of action

Glycopeptide antibiotics (e.g., vancomycin) bind to the terminal D-alanyl-D-alanine motif of peptidoglycan precursors, inhibiting transglycosylation and transpeptidation required for cell wall cross-linking, and thereby blocking bacterial cell wall synthesis[6][3][2].

03

Biological functions

Cell wall biosynthesisMaintenance of cell shapeProtection against osmotic stressBacterial cell division
04

Disease associations

InfectionAntibiotic resistance
05

Safety considerations

Bacterial resistance is a therapeutic challenge, especially mediated by replacement of D-Ala-D-Ala with D-Ala-D-Lac or D-Ala-D-Ser, leading to reduced antibiotic binding[6][3].Narrow therapeutic index and nephrotoxicity risks of glycopeptide antibiotics targeting D-Ala-D-Ala.
06

Interacting drugs

Vancomycin

3 more in the full profile.

07

Biomarkers

Presence of D-Ala-D-Ala in bacterial cell walls can indicate the existence of glycopeptide-susceptible bacteria (used for patient selection with vancomycin or related antibiotics)[6].

Beyond the preview

Go deeper on Terminal D-alanyl-D-alanine of peptidoglycan precursor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Terminal D-alanyl-D-alanine of peptidoglycan precursor.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call